Siddhartha Goutam
Overview
Explore the profile of Siddhartha Goutam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar D, Chakraborty R, Goutam S, Mukherjee S, Mondal D, Roy R, et al.
J Innov Card Rhythm Manag
. 2024 Jul;
15(6):5911-5916.
PMID: 38948661
Bradyarrhythmias, characterized by heart rates of <60 bpm due to conduction issues, carry risks of sudden cardiac death and falls. Pacemaker implantation is a standard treatment, but the interplay between...
2.
Goutam S, Ghosh S, Stosky J, Tam A, Quirk S, Fairchild A, et al.
Curr Oncol
. 2023 Dec;
30(12):10043-10056.
PMID: 38132364
Radiotherapy (RT) is often utilized for symptom control at the end of life. Palliative RT (pRT) may not be taken to completion by patients, thus decreasing clinical benefits and adversely...
3.
Woo T, Stukalin I, Ding P, Goutam S, Sander M, Ewanchuk B, et al.
Curr Oncol
. 2023 Oct;
30(10):8936-8947.
PMID: 37887546
: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups. A retrospective,...
4.
Meyers D, Pasternak M, Dolter S, Grosjean H, Lim C, Stukalin I, et al.
JTO Clin Res Rep
. 2023 Apr;
4(4):100482.
PMID: 37090101
Introduction: Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC are difficult to extrapolate to real-world practice given the exclusion of patients with poor (i.e., ≥2) Eastern Cooperative Oncology...
5.
Stukalin I, Navani V, Gupta M, Ruan Y, Boyne D, OSullivan D, et al.
Oncologist
. 2023 Apr;
28(9):812-822.
PMID: 37011230
Background: Risk stratification tools for patients with advanced melanoma (AM) treated with immune checkpoint inhibitors (ICI) are lacking. We identified a new prognostic model associated with overall survival (OS). Patients...
6.
Dehury S, Mohapatra S, Das H, Goutam S, Kaushik C
Indian J Pharmacol
. 2023 Mar;
55(1):6-13.
PMID: 36960515
Objectives: Chronic constipation (CC), a common functional gastrointestinal disorder, has laxatives as its mainstay of treatment. Refractoriness to laxatives calls for better treatment options. Prucalopride is a novel, well-tolerated enterokinetic...
7.
Swain T, Goutam S, Jena R, Rout N
Indian J Pharmacol
. 2022 Dec;
54(5):349-352.
PMID: 36537404
Background: Imatinib mesylate is the cornerstone therapy in the management of chronic myeloid leukemia (CML). Monitoring of adverse drug reactions (ADRs) of imatinib in our patients is very important to...
8.
Watson A, Goutam S, Stukalin I, Ewanchuk B, Sander M, Meyers D, et al.
JAMA Netw Open
. 2022 Dec;
5(12):e2245596.
PMID: 36480204
Importance: Immune-related adverse events (irAEs) due to immune checkpoint blockade (ICB) have been shown to be positively associated with survival. Among patients with metastatic melanoma, evidence supporting this association has...
9.
Goutam S, Stukalin I, Ewanchuk B, Sander M, Ding P, Meyers D, et al.
Curr Oncol
. 2022 Oct;
29(10):7695-7704.
PMID: 36290885
Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of...
10.
Grosjean H, Dolter S, Meyers D, Ding P, Stukalin I, Goutam S, et al.
Curr Oncol
. 2021 Oct;
28(5):4213-4222.
PMID: 34677275
The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical...